Enable Injections Unveils Plans for Manufacturing Facilities and Corporate Headquarters Expansion

Wednesday, February 14, 2024

Enable Injections, a key player in the development and production of the enFuse® wearable technology platform, has unveiled plans for expansion. The company intends to establish a new large-scale manufacturing facility in Springdale, Ohio, and enhance its corporate headquarters in Evendale, Ohio. The forthcoming 90,000 square-foot Manufacturing Center of Excellence will facilitate in-house production and supply of Enable's enFuse medicine delivery technology.

This innovative technology enables patients to self-administer large-volume medications subcutaneously, eliminating the need for an IV or syringe pump. The expanded facility aims to streamline production processes, accelerating the availability of the enFuse system to patients and healthcare providers. This strategic expansion follows U.S. FDA approval and the successful launch of Enable's inaugural enFuse combination product.

The new Manufacturing Center of Excellence is slated to be operational by the end of 2024, contributing to the creation and retention of over 450 jobs in the Cincinnati area over the next decade. In addition to the Springdale facility, Enable will renovate its Evendale headquarters, which currently houses GMP-compliant manufacturing space, labs, and administrative areas to support the demand for enFuse in both clinical and commercial settings.




Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024